Future directions in the evaluation of c-MET-driven malignancies

Therapeutic Advances in Medical Oncology

Volumn 3, Issue 1, 2011, Pages S51-S60

  de Bono, Johann S ^a   Yap, Timothy A ^b  

^a The Institute of Cancer Research ^*

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

biomarkers; c MET; drug development; patient selection; targeted therapy; treatment resistance

Indexed keywords

EID: 84997859208     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834011423540     Document Type: Review

References (57)

1. Adjei A.A. Sosman J.A. Martell R.E. Dy G.K. Goff L.W. Ma W.W. (2011) Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib. J Clin Oncol 29(Suppl): abstract 3034.
2. Bean J. Brennan C. Shih J.-Y. Riely G. Viale A. Wang L. (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104: 20932–20937.
3. Beau-Faller M. Ruppert A.M. Voegeli A.C. Neuville A. Meyer N. Guerin E. (2008) MET gene copy number in non-small cell lung cancer: Molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort. J Thorac Oncol 3: 331–339.
4. Bessudo A. Bendell J.C. Gabrail N.Y. Kopp M.V. Mueller L. Hart L.L. (2011) Phase I results of the randomized, placebo-controlled, phase I/II study of the novel oral c-MET inhibitor, tivantinib (ARQ 197), irinotecan (CPT-11), and cetuximab in patients with wild-type KRAS metastatic colorectal cancer who have received front-line systemic therapy. J Clin Oncol 29(Suppl): abstract 3582.
5. Birchmeier C. Birchmeier W. Gherardi E. VandeWoude G.F. (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915–925.
6. Bladt F. Riethmacher D. Isenmann S. Aguzzi A. Birchmeier C. (1995) Essential role for the c-MET receptor in the migration of myogenic precursor cells into the limb bud. Nature 376: 768–771.
7. Boccaccio C. Comoglio P.M. (2006) Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 6: 637–645.
8. Bonine-Summers A.R. Aakre M.E. Brown K.A. Arteaga C.L. Pietenpol J.A. Moses H.L. (2007) Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biol Ther 6: 561–570.
9. Bowers D.C. Fan S. Walter K.A. Abounader R. Williams J.A. Rosen E.M. (2000) Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. Cancer Res 60: 4277–4283.
10. Cappuzzo F. Marchetti A. Skokan M. Rossi E. Gajapathy S. Felicioni L. (2009) Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung. J Clin Oncol 27: 1667–1674.
11. Cecchi F. Rabe D.C. Bottaro D.P. (2010) Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer 46: 1260–1270.
12. Cheng T.L. Chang M.Y. Huang S.Y. Sheu C.C. Kao E.L. Cheng Y.J. (2005) Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer. Chest 128: 1453–1460.
13. Christensen J.G. Burrows J. Salgia R. (2005) c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 225: 1–26.
14. Comoglio P.M. Giordano S. Trusolino L. (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nature Rev Drug Discov 7: 504–516.
15. Cunningham D. Humblet Y. Siena S. Khayat D. Bleiberg H. Santoro A. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345.
16. Dai Q. Ling Y.H. Lia M. Zou Y.Y. Kroog G. Iwata K.K. (2005) Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. Clin Cancer Res 11: 1572–1578.
17. de Bono J.S. Ashworth A. (2010) Translating cancer research into targeted therapeutics. Nature 467: 543–549.
18. de Bono J.S. Tolcher A.W. Rowinsky E.K. (2003) The future of cytotoxic therapy: selective cytotoxicity based on biology is the key. Breast Cancer Res 5: 154–159.
19. Eder J.P. Vande Woude G.F. Boerner S.A. LoRusso P.M. (2009) Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15: 2207–2214.
20. Engelman J.A. Zejnullahu K. Mitsudomi T. Song Y. Hyland C. Park J.O. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039–1043.
21. Gordon M.S. Sweeney C.S. Mendelson D.S. Eckhardt S.G. Anderson A. Beaupre D.M. (2010) Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res 16: 699–710.
22. Janne P.A. Gray N. Settleman J. (2009) Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nature Rev Drug Discov 8: 709–723.
23. Jo M. Stolz D.B. Esplen J.E. Dorko K. Michalopoulos G.K. Strom G.C. (2000) Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 275: 8806–8811.
24. Knuefermann C. Lu Y. Liu B. Jin W. Liang K. Wu L. (2003) HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22: 3205–3212.
25. Kong-Beltran M. Seshagiri S. Zha J. Zhu W. Bhawe K. Mendoza N. (2006) Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 66: 283–289.
26. Kurzrock R. Sherman S.I. Ball D.W. (2011) Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 29: 2660–2666.
27. Lasagna N. Fantappie O. Solazzo M. Morbidelli L. Marchetti S. Cipriani G. (2006) Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines. Cancer Res 66: 2673–2682.
28. Liu X. Yao W. Newton R.C. Scherle P.A. (2008) Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs 17: 997–1011.
29. Liu Y. Yang J. (2006) Hepatocyte growth factor: new arsenal in the fights against renal fibrosis?. Kidney Int 70: 238–240.
30. Ma P.C. Jagadeeswaran R. Jagadeesh S. Tretiakova M.S. Nallasura V. Fox E.A. (2005) Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 65: 1479–1488.
31. Ma P.C. Kijima T. Maulik G. Fox E.A. Sattler M. Griffin J.D. (2003) c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 63: 6272–6281.
32. Ma P.C. Schaefer E. Christensen J.G. Salgia R. (2005) A selective small molecule c-MET inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res 11: 2312–2319.
33. Ma P.C. Tretiakova M.S. MacKinnon A.C. Ramnath N. Johnson C. Dietrich S. (2008) Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 47: 1025–1037.
34. McDermott U. Settleman J. (2009) Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. J Clin Oncol 27: 5650–5659.
35. Mueller K.L. Hunter L.A. Ethier S.P. Boerner J.L. (2008) Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res 68: 3314–3322.
36. Okada H. Kalluri R. (2005) Cellular and molecular pathways that lead to progression and regression of renal fibrogenesis. Curr Mol Med 5: 467–474.
37. Pillay V. Allaf L. Wilding A.L. Donoghue J.F. Court N.W. Greenall S.A. (2009) The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia 11: 448–458.
38. Rosen P.J. Sweeney C.J. Park D.J. Beaupre D.M. Deng H. Leitch I.M. (2010) A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clin Cancer Res 16: 2677–2687.
39. Sandler A. Schiller J.H. Hirsh V. Sequist L.V. Soria J. Von Pawel J. (2011) A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC). J Clin Oncol 29(Suppl): abstract TPS217.
40. Sarker D. Workman P. (2007) Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res 96: 213–268.
41. Schiller J.H. Akerley W.L. Brugger W. Ferrari D. Garmey E.G. Gerberet D.E. (2010) Results from ARQ 197-209: a global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 28(Suppl): abstract LBA7502.
42. Schmidt C. Bladt F. Goedecke S. Brinkmann V. Zschiesche W. Sharpe M. (1995) Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373: 699–702.
43. Sharma S. Bell D. Settleman J. Haber D. (2007) Epidermal growth factor receptor mutations in lung cancer. Nature Rev Cancer 7: 169–181.
44. Sharma S. Settleman J. (2007) Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 21: 3214–3231.
45. Slamon D.J. Leyland-Jones B. Shak S. Fuchs H. Paton V. Bajamonde A. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792.
46. Spigel D.R. Ervin T.J. Ramlau R. Daniel D.B. Goldschmidt J.H. Blumenschein G.R. (2011) Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 29(Suppl): abstract 7505.
47. Stommel J.M. Kimmelman A.C. Ying H. Nabioullin R. Ponugoti A.H. Wiedemeyer R. (2007) Coactivation of receptor tyrosine kinases affects the response of tumour cells to targeted therapies. Science 318: 287–290.
48. Tan E. Park K. Lim W.T. Ahn M. Ng Q.S. Ahn J.S. (2011) Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC. J Clin Oncol 29(Suppl): abstract 7571.
49. Toschi L. Janne P.A. (2008) Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer. Clin Cancer Res 14: 5941–5946.
50. Trusolino L. Comoglio P.M. (2002) Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nature Rev Cancer 2: 289–300.
51. Ueki T. Kaneda Y. Tsutsui H. Nakanishi K. Sawa Y. Morishita R. (1999) Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nature Med 5: 226–230.
52. Watanabe M. Ebina M. Orson F.M. Nakamura A. Kubota K. Koinuma D. (2005) Hepatocyte growth factor gene transfer to alveolar septa for effective suppression of lung fibrosis. Mol Ther 12: 58–67.
53. Workman P. (2002) Challenges of PK/PD measurements in modern drug development. Eur J Cancer 38: 2189–2193.
54. Workman P. (2003) How much gets there and what does it do? The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des 9: 891–902.
55. Yap T.A. de Bono J.S. (2010) Targeting the HGF/c-Met axis: state of play. Mol Cancer Ther 9: 1077–1079.
56. Yap T.A. Olmos D. Brunetto A.T. Tunariu N. Barriuso J. Riisnaes R. (2011) Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 29: 1271–1279.
57. Yap T.A. Sandhu S.K. Workman P. de Bono J.S. (2010) Envisioning the future of early anti-cancer drug development. Nature 10: 514–523.